EBS Q2 2024 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$255M-24.6% YoY

Gross Profit

-$66M-25.7% margin

Operating Income

-$204M-79.9% margin

Net Income

-$283M-111.2% margin

EPS (Diluted)

$-5.38

QoQ Revenue Growth

-15.2%

Cash Flow

Operating Cash Flow

$48M

Free Cash Flow

$43M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$1.1B

Stockholders' Equity

$386M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$255M	$338M	-24.6%
Gross Profit	-$66M	$123M	-153.1%
Operating Income	-$204M	-$293M	+30.5%
Net Income	-$283M	-$261M	-8.3%

Revenue Segments

Product

$183M72%

Contract Development And Manufacturing

$65M25%

Contracts and Grants

$7M3%

Geographic Segments

Services Segment

$65M100%